Biodesign® Hernia Graft

Study demonstrates safety and efficacy of Biodesign in treatment of complex hernias[1]

Retrospective clinical study

23 patients

Product	Number of patients	Recurrences
Biodesign	**14**	**7%**
Synthetic mesh	**6**	**17%**
Permacol®*	**3**	**33%**

GRADE III-IV HERNIAS

can be treated successfully with the Biodesign Hernia Graft.

Twenty-three patients who underwent ventral hernia repair with a mesh or graft were retrospectively analysed. Of these, 14 patients received a Biodesign graft, 6 received synthetic mesh, and 3 received Permacol.

All procedures were performed using components separation with a mesh or graft to approximate the midline.

Median patient age was 57 (age range: 20-76).

All hernia procedures were Grade III or Grade IV cases in patients with various complications. Of the 23, 15 had stomas, and eight had enterocutaneous fistulas.

Median follow-up was 17 months (range: 2-48 months).

At follow-up, reported complications included seromas (n = 5), recurrence (n = 3), infection (n = 3), wound dehiscence (n = 5), and ischemic stoma (n = 2). The surgeons concluded that drains must be used to present seromas and that the ischemic stomas resulted from a too-tight repair around the stoma.

Midline closure was achieved in 80% of the cases, which surgeons determined was critical to prevent recurrences.

1. Nockolds CL, Hodde JP, Rooney PS. Abdominal wall reconstruction with components separation and mesh reinforcement in complex hernia repair. *BMC Surg.* 2014;14:25.

* Permacol is a registered trademark of Covidien AG Corporation.

COOK® BIOTECH

cookbiotech.eu